Coeptis Therapeutics Inc
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy tec… Read more
Coeptis Therapeutics Inc (COEP) - Net Assets
Latest net assets as of September 2025: $13.02 Million USD
Based on the latest financial reports, Coeptis Therapeutics Inc (COEP) has net assets worth $13.02 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($16.28 Million) and total liabilities ($3.26 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $13.02 Million |
| % of Total Assets | 79.95% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 13157.12 |
Coeptis Therapeutics Inc - Net Assets Trend (2004–2024)
This chart illustrates how Coeptis Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Coeptis Therapeutics Inc (2004–2024)
The table below shows the annual net assets of Coeptis Therapeutics Inc from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $3.87 Million | -13.16% |
| 2023-12-31 | $4.45 Million | -7.29% |
| 2022-12-31 | $4.80 Million | +104.34% |
| 2021-12-31 | $2.35 Million | +145.70% |
| 2020-12-31 | $-5.14 Million | -32874.75% |
| 2019-12-31 | $15.69K | -12.46% |
| 2018-12-31 | $17.93K | +103.25% |
| 2005-12-31 | $-551.66K | -108.95% |
| 2004-12-31 | $-264.01K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Coeptis Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 9529886000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $212.00 | 0.01% |
| Other Components | $101.42 Million | 3184.09% |
| Total Equity | $3.19 Million | 100.00% |
Coeptis Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Coeptis Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Thai Coconut Public Company Limited
BK:COCOCO
|
$49.18 Million |
|
Tata Steel (Thailand) Public Company Limited
BK:TSTH
|
$49.19 Million |
|
Paxman AB
PINK:PXMBF
|
$49.22 Million |
|
Chino Commercial Bancorp
PINK:CCBC
|
$49.22 Million |
|
VirTra Inc
NASDAQ:VTSI
|
$49.15 Million |
|
Adicet Bio Inc
NASDAQ:ACET
|
$49.12 Million |
|
PEDEVCO Corp
NYSE MKT:PED
|
$49.12 Million |
|
Solytech Enterprise Corp
TW:1471
|
$49.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Coeptis Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 4,453,329 to 3,185,164, a change of -1,268,165 (-28.5%).
- Net loss of 10,877,412 reduced equity.
- New share issuances of 4,014,001 increased equity.
- Other factors increased equity by 5,595,246.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-10.88 Million | -341.5% |
| Share Issuances | $4.01 Million | +126.02% |
| Other Changes | $5.60 Million | +175.67% |
| Total Change | $- | -28.48% |
Book Value vs Market Value Analysis
This analysis compares Coeptis Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-141.71 | $11.70 | x |
| 2005-12-31 | $-296.11 | $11.70 | x |
| 2018-12-31 | $0.03 | $11.70 | x |
| 2019-12-31 | $0.00 | $11.70 | x |
| 2020-12-31 | $-0.25 | $11.70 | x |
| 2021-12-31 | $2.30 | $11.70 | x |
| 2022-12-31 | $0.34 | $11.70 | x |
| 2023-12-31 | $0.17 | $11.70 | x |
| 2024-12-31 | $1.65 | $11.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Coeptis Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -341.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.80x
- Recent ROE (-341.50%) is below the historical average (-247.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | 0.00% | 0.00x | 0.00x | $2.67 Million |
| 2005 | 0.00% | 0.00% | 0.00x | 0.00x | $-288.83K |
| 2018 | -39.45% | 0.00% | 0.00x | 4.46x | $-8.87K |
| 2019 | -14.24% | 0.00% | 0.00x | 10.93x | $-3.80K |
| 2020 | 0.00% | -29765.89% | 0.10x | 0.00x | $-8.64 Million |
| 2021 | -572.16% | -17932.37% | 0.01x | 2.88x | $-13.68 Million |
| 2022 | -782.25% | 0.00% | 0.00x | 1.65x | $-38.05 Million |
| 2023 | -477.54% | 0.00% | 0.00x | 1.78x | $-21.71 Million |
| 2024 | -341.50% | 0.00% | 0.00x | 2.80x | $-11.20 Million |
Industry Comparison
This section compares Coeptis Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Coeptis Therapeutics Inc (COEP) | $13.02 Million | 0.00% | 0.25x | $49.18 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |